Changes in multi‐gene cancer panels for children: A 4‐year retrospective review
Open Access
- 26 June 2025
- journal article
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (4) , e70075
Abstract
The multi‐gene panel is the most utilized genetic test to evaluate for germline cancer predisposition syndromes. However, the rate of change of commercial multigene panels is not well understood, and its value as a standalone test has also not been investigated. We conducted a retrospective chart review of the UPMC Children's Hospital of Pittsburgh Cancer Predisposition Program's genetic testing results to evaluate how multigene panels for pediatric and young adult patients with cancer have changed in size and scope from 2018 to 2022. We find that multigene panels show a trend of growing larger in number of genes included over time and explore the utility of additional genetic testing after the initial round of multi‐gene panel testing. We demonstrate heterogeneity between commercial genetic testing laboratories and their panels over time, signifying a need for equity among genetic testing panels and vigilance among physicians and genetic counselors ordering panel‐based testing.Keywords
This publication has 20 references indexed in Scilit:
- Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel TestingAnnals of Surgical Oncology, 2019
- Case-based review: atypical teratoid/rhabdoid tumorNeuro-Oncology Practice, 2018
- The Perils of Single-Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next-Generation SequencingThe Oncologist, 2018
- Genetic predisposition in children with cancer – affected families' acceptance of Trio-WESEuropean Journal of Pediatrics, 2017
- Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patientsBreast Cancer Research and Treatment, 2017
- Atypical teratoid/rhabdoid tumors: challenges and search for solutionsCancer Management and Research, 2016
- Germline Mutations in Predisposition Genes in Pediatric CancerNew England Journal of Medicine, 2015
- Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk AssessmentJAMA Oncology, 2015
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthJAMA, 2015
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010